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Abstract
Zika virus has been known for more than half a century. Its clinical 
significance was just recently discovered, after the epidemic of Zika virus 
emerged in South and Central America. A task force established in 2015 by 
the Brazil Ministry of Health investigated the possible association between 
congenital Zika infection and microcephaly in fetuses and newborns. Since 
then more and more evidence emerged, supporting this hypothesis. The 
objective of this article is to review and summarize the currently available 
literature regarding Zika virus from a neonatologist’s standpoint and provide 
some guidance to medical providers who may have to care for potentially 
exposed pregnant patients and their newborns. 
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Introduction
Since January 2016 the topic of Zika virus (also known as ZIKV) 
infection has been constantly present in the headlines of the largest news 
agencies and the most famous medical journals. The suspected association 
between Zika virus infection and microcephaly in neonates raised the level 
Review
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of anxiety especially in the population of pregnant 
women and their medical providers. 
Background
Zika virus is a mosquito-borne RNA Flavivirus. 
There are 2 known lineages: an African and an 
Asian [1]. The virus was discovered by D.W.A. 
Dick for the first time in 1947, but not described 
in the literature until 1952. It was isolated from a 
febrile Rhesus monkey found in the Zika Forest 
(hence the name) in Uganda. The first documented 
human case was subsequently isolated in Nigeria 
in 1954 [2, 3]. Before 2007 only isolated human 
disease cases were reported from countries in 
Asia and Africa. In 2007 the first documented 
outbreak was reported in Yap State, Federated 
States of Micronesia, followed by outbreaks in 
Southeast Asia, the Western Pacific region and, 
most recently, in 2015 in Brazil [4]. On February 
1, 2016, WHO has declared the problem of Zika 
virus infection a “Public Health Emergency 
of International Concern” [5]. The number of 
documented cases of Zika virus infection is 
constantly at the rise, both worldwide as well as 
on US territories [6, 7]. Fig. 1 shows the countries 
worldwide with documented active Zika virus 
transmissions, as of September 23, 2016, as per 
CDC [8].
Transmission occurs most commonly via an 
insect vector [1]. There are 2 known vectors: Aedes 
aegypti also known as the Yellow fever mosquito; 
and Aedes albopictus – the Asian tiger mosquito. 
Aedes aegypti is the main vector and can also spread 
dengue fever, chikungunya, yellow fever viruses, 
and other diseases. It originated from Africa, but 
can also be found in most tropical and subtropical 
regions of the world (including: South and Central 
America, Asia and Polynesia). Aedes albopictus 
is more common in Asia, some regions of Europe 
and can also be found in North America. New 
research has shown that both species are capable 
of spreading in the United States further North as 
initially anticipated, hence posing a higher risk 
of infection transmission [1, 6, 9]. Some authors 
also hypothesize that there might be a genetic 
basis causing the evolution into new viral types 
with the enhanced ability to infect humans [10]. 
The recent epidemics also revealed other ways of 
transmission. It is known that the infection can be 
acquired transplacentally and intrapartum [11-13], 
via blood transfusions (no documented cases in 
the US, but suspected cases in Brazil) [13], as well 
as via sexual contact (the virus can be detected in 
semen for up to 2 weeks after the acute illness) [14]. 
Organ transplantation could potentially also pose a 
risk for transmission, although there are currently 
no known cases worldwide.  An interesting issue is 
Figure 1. Zika virus (also known as ZIKV) reported active transmission as of September 23, 2016. Data are from the 
Centers for Disease Control and Prevention (CDC) [8]. 
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also the risk of transmission via breastfeeding, the 
virus has been detected in breastmilk in 2 cases in 
Polynesia [15].
The majority of affected patients is 
asymptomatic (80%). The incubation period for 
Zika virus disease is still unknown, but is likely 
to be a few days to a week. Of those patients 
who present with symptoms, the most common 
complaints are very nonspecific: low-grade fever, 
maculopapular rash, arthralgia, non-purulent 
conjunctivitis, myalgia and headache. The illness 
is usually mild with symptoms lasting for several 
days to a week, rarely causing a severe sickness 
requiring medical attention in a hospital setting 
or causing death [16]. There are known cases 
in the literature of neurological complications 
associated with Zika virus infection. Both during 
the outbreak in French Polynesia in 2013-2014 
and in Brazil in 2015 patients were presenting with 
symptoms resembling Guillain-Barré syndrome, 
an autoimmune disease characterized by ascending 
paralysis [17, 18]. 
There is currently no curative treatment 
available, and the management of Zika positive 
patients is based on supportive measures: 
hydration, analgesics and antipyretics. The key in 
decreasing the numbers of infected patients lies 
in prevention, mainly with personal protection, 
repellents, barrier contraception [1, 17]. In March 
2016 the New York State Government suggested 
providing to health care providers “Zika Virus 
Protection Kits” containing repellents, condoms 
and larvicide tablets to treat standing water [19].
Pathogenesis of microcephaly and other 
anomalies due to Zika virus infection and 
hypothesis of causation
The clinical significance of a congenital Zika 
virus infection was discovered for the first time in 
2015 in Brazil. In early 2015, an outbreak of Zika 
was identified in northeast Brazil. By September, 
reports of a 20-fold increase in the number of infants 
born with microcephaly in Zika-affected areas began 
to appear. Initially Zika RNA was identified from 
the amniotic fluid of 2 women whose fetuses were 
diagnosed with microcephaly. Subsequently more 
evidence emerged confirming the presence of Zika 
virus genetic material in newborn tissues obtained 
from neonates with microcephaly shortly after birth 
or after termination of pregnancy [17, 20-22].
Viral tropism of Zika to the brain has been 
known since 1952. Already back then, research 
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was suggesting that the virus can cross the blood- 
brain barrier. In mice models the virus infected 
both neurons and glia producing a variety of 
intracytoplasmic inclusions [2, 3]. Current studies 
also report the highest levels of viremia in samples 
obtained from the brain tissue of infected fetuses 
or neonates. One of the current hypothesis by Tetro 
[23] links the pathogenesis of Zika microcephaly 
with centrosome abnormalities. Centrosomes are 
involved in mitosis, migration, polarity and proper 
trafficking of vesicles. Abnormal function of these 
organelles can delay mitosis, increase apoptosis, 
cause improper neural stem cell orientation and 
premature neuronal differentiation, as well as 
decrease progenitor cells. By influencing all these 
processes, it can lead to reduction of brain formation 
subsequently causing a reduced brain size. After 
the epidemics in Brazil emerged, several animal 
studies were performed on mice to investigate the 
mode of transmission on a more cellular level. 
The investigators have found that Zika virus most 
likely preferentially injures the cortical neuronal 
progenitor cells [12]. The death of progenitor 
cells initiated by viral induced inflammation could 
explain the brain malformations, microcephaly and 
cortical thinning. Other authors hypothesize that 
there are strong similarities between Zika virus 
infection and hypervitaminosis A, a known in utero 
teratogen. In the model described by Mawson [24], 
an early infection with the virus activates a retinoic 
cascade in the liver resulting in an increased 
production of retinoic acid. Elevated retinoic acids 
levels cause cholestatic liver damage and then 
subsequently neuronal apoptosis and necrosis, 
leading to growth restriction, microcephaly 
and ophthalmologic defects. Rasmussen [25] 
published an interesting analysis reviewing the 
association between prenatal Zika infection, 
microcephaly and other brain abnormalities. By 
applying specific criteria for the evaluation of 
potential teratogens (also known as Bradford Hill 
criteria) on all available evidence they concluded 
that there is sufficient evidence supporting the 
causal relationship between congenital Zika virus 
infection and microcephaly. 
Birth defects associated with congenital Zika 
virus infection
Besides brain abnormalities (microcephaly, 
ventriculomegaly, intracranial calcifications, 
neuronal migration disorders, lissencephaly, 
pachygyria, corpus callosum dysgenesis) [20-22, 
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26-29] and eye abnormalities (microphthalmia, 
focal pigment mottling of the retina, chorioretinal 
atrophy, optic nerve abnormalities, cataracts, eye 
asymmetry, intraocular calcifications, macular 
atrophy, lens subluxation) [24, 30], congenital Zika 
virus infection can be also associated with congenital 
contractures, arthrogryposis and club feet [26]. 
Additionally, growth restriction was noted in the 
affected fetuses and neonates, raising the suspicion 
of abnormal placental development or placental 
insufficiency caused by Zika virus infection [12, 
22]. The relationship between the timing of the 
acute maternal infection and the subsequent fetal 
abnormalities still remains unknown. Some studies 
suggest a 1% chance of developing microcephaly 
if the Zika virus infection and subsequent insult 
occurred during the first trimester of pregnancy. 
This theory corresponds with the known fact, that 
the most crucial stages of brain development occur 
during that time. Stillbirth has been associated with 
acute viral infection late in pregnancy [29].
Diagnostic approach and management in 
suspected neonatal cases of Zika virus infection
The CDC guidelines recommend testing of 
pregnant women with a possible exposure to Zika 
virus. Tests can be performed on both serum and 
amniotic fluid – one must remember though the 
risks of amniocentesis itself, which can result in 
fetal loss in about 0.1% of cases [31]. Additionally, 
it is still not known how sensitive and specific the 
available testing is and if a positive result is actually 
predictive of a subsequent fetal abnormality. 
The currently available diagnostic opportunities 
include PCR testing for viral RNA, detection of 
Zika virus-specific IgM antibodies using ELISA 
and plaque reduction neutralization test (PRNT) 
for Zika antibodies. Viral RNA can be detected 
during the first 7 days of illness, after that the level 
of viremia decreases. During that period, molecular 
testing is recommended. However, a negative RT-
PCR performed on days 5-7 of the acute illness 
does not exclude Zika virus infection and should 
be verified with serological testing. Zika virus-
specific IgM antibodies might be detected as early 
as on the 4th day of the acute illness and they can 
persist 2-12 weeks. However, serum collected 
within the first 7 days might not detect specific 
Zika virus antibodies. Hence it is recommended 
to postpone serologic testing until after 7 days 
of illness. Cross reactivity might occur between 
Zika virus antibodies and antibodies against 
other Flaviviridae (especially with the increasing 
numbers of tourists being vaccinated for Yellow 
Fever or Japanese Encephalitis), hence every 
positive antibody test should be confirmed with 
a plaque-reduction neutralization test (PRNT). A 
4-fold or higher increase in specific Zika virus antibody 
titers is considered positive [26, 32]. In the case of 
a positive Zika test as per CDC serial ultrasound 
examinations should be considered to monitor 
fetal growth and anatomy every 3-4 weeks. The 
pregnant woman should be referred to a Maternal 
Fetal Medicine and Infectious Diseases specialist. 
After delivery histopathologic examination of the 
placenta and umbilical cord is recommended, as 
well as testing of frozen placental tissue and cord 
tissues for Zika virus RNA and testing of cord 
serum for Zika and dengue virus IgM along with 
neutralizing antibodies. In the situation of a fetal 
loss due to suspected Zika infection, CDC also 
highly recommends Zika virus PCR testing and 
immunohistochemical staining to be performed 
on the fetal tissues, including umbilical cord 
and placenta. Zika testing is also recommended 
for infants with microcephaly or intracranial 
calcifications born to women who traveled to or 
resided in areas with Zika virus transmission 
while being pregnant as well as for infants born to 
mothers with a positive or inconclusive test results 
for Zika virus infection. A thorough physical exam 
should be performed in all cases of suspected 
congenital Zika infection, including an evaluation 
for neurologic abnormalities, dysmorphic 
features, splenomegaly, hepatomegaly, and rash 
or other skin lesions; a hearing evaluation and 
an ophthalmologic evaluation. Laboratory testing 
for infants includes: serum samples from the 
umbilical cord or directly from the baby within 
2 days after birth; CSF if clinically warranted; 
frozen and fixed placenta tissue. All cases of 
confirmed Zika infection should be reported to the 
state, territorial, or local health department and 
should be monitored for additional guidance as it 
is released. Additional hearing screen should be 
conducted at age 6 months, due to the possibility of 
co-occurrence of CMV infection. Providers should 
carefully evaluate occipito-frontal circumference 
and developmental milestones at every well child 
visit [6, 26, 31, 33]. Although the virus has been 
detected in breastmilk in the past in 2 cases in 
Polynesia, WHO still recommends breastfeeding, 
possibly attributing the infection not directly to 
breastfeeding but to close contact between the 
mother and the infant [15].
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Conclusions
What are our hopes for the future? Some 
experts are hoping that the Zika virus will behave 
similarly to rubella: most of the population gets it 
and subsequently most of the population becomes 
immune. Nevertheless, several research labs are 
currently working on developing a vaccine, which 
should soon enter the first phase of clinical trials 
[34, 35].
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